Insilico Medicine Partners with TaiGen for AI-Driven Anemia Treatment in Greater China
Key Insights
Insilico Medicine (search) has granted TaiGen Biotechnology (search) exclusive rights to develop and commercialize ISM4808, an AI-discovered PHD (search) inhibitor for chronic kidney disease-related anemia in Greater China.
The novel compound targets the Nobel Prize-winning HIF-α (search) pathway and was designed using Insilico's Chemistry42 AI platform within just 12 months.
ISM4808 demonstrated compelling preclinical efficacy with lower effective doses in CKD rat models and received IND clearance from China's CDE in 2023.
Insilico Medicine (search), a clinical-stage AI-driven drug discovery company, has entered into an exclusive licensing agreement with TaiGen Biotechnology (search) to develop and commercialize ISM4808, an artificial intelligence-discovered PHD (search) inhibitor for treating anemia associated with chronic kidney disease (CKD). The partnership grants TaiGen exclusive rights for development, commercialization, and sub-licensing across Greater China, including Mainland China, Hong Kong, Macau, and Taiwan.
AI-Powered Drug Discovery Breakthrough
ISM4808 represents a significant achievement in AI-driven pharmaceutical development, having been designed, synthesized, and tested within a 12-month window using Insilico's proprietary Chemistry42 engine. The compound was nominated in 2022 as a potential best-in-class PHD (search) inhibitor targeting the Nobel Prize-winning HIF-α (search) pathway for treating CKD-related anemia through EPO (search) induction and improved iron utilization for enhanced blood cell replacement.
The discovery and development journey of the ISM4808 series was published in the Journal of Medicinal Chemistry in January 2024, highlighting the novelty and efficiency of Insilico's AI-driven drug research and development workflow.
Compelling Preclinical Results
In preclinical studies, ISM4808 demonstrated compelling potency across both in vitro and in vivo assays, showing lower effective doses in CKD rat models compared to existing treatments. The compound exhibited promising oral drug-like properties with favorable in vitro ADME characteristics and promising pharmacokinetic profiles across animal models. Additionally, ISM4808 showed a favorable safety profile characterized by higher maximum tolerated doses and broad safety margins.
The program achieved a significant regulatory milestone when it received IND clearance from the Center for Drug Evaluation (CDE) in China in 2023, enabling the initiation of human clinical trials.
Addressing Critical Medical Need
Chronic kidney disease accounts for over 1.5 million deaths annually worldwide, with more than one in seven people with kidney disease developing anemia due to reduced erythropoietin (EPO (search)) production and shorter red blood cell lifespans. Current treatments primarily focus on symptom relief, including fatigue, shortness of breath, body aches, and dizziness, with the goal of improving quality of life rather than providing a cure.
Strategic Partnership and Market Opportunity
Under the licensing agreement terms, Insilico is eligible for payments including upfront fees, development and sales-based milestone payments, and tiered royalties on net sales, with a total potential value in the double-digit millions of dollars.
"We are delighted to collaborate with TaiGen Biotech," said Feng Ren, PhD (search), Co-CEO and CSO of Insilico Medicine (search). "Powered by AI, Insilico has efficiently nominated two novel PHD inhibitors for different indications. ISM5411, a gut-restricted molecule for inflammatory bowel disease, has completed two Phase I trials, and demonstrated a favorable safety profile, further strengthened our confidence in PHD-targeting programs."
Kuo-Lung Huang, Chairman of TaiGen Biotechnology (search), emphasized the market opportunity: "With over a million dialysis patients in Mainland China, the PHD (search) inhibitor market is experiencing explosive growth, having surged from approximately 50 million RMB to 2.45 billion RMB in just 5 years. As oral drugs progressively replace traditional injectables, TaiGen is dedicated to advancing this innovative program to meet the urgent clinical need for convenient and compliant therapies."
Company Backgrounds
Insilico Medicine (search) operates as a leading AI-driven biotech company utilizing its proprietary Pharma.AI platform and automated laboratory systems to accelerate drug discovery across multiple therapeutic areas including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders.
TaiGen Biotechnology (search), founded in 2001 and listed on the Taiwan OTC Market in 2014, operates as a fully integrated pharmaceutical company specializing in innovative small-molecule drugs, particularly anti-infectives. The company has demonstrated expertise in drug discovery, development, regulatory approval, and multi-country clinical trials, with its flagship antibiotic Taigexyn® (Nemonoxacin) approved in Taiwan, China, and Russia.